期刊
HEART VIEWS
卷 21, 期 2, 页码 97-103出版社
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_20_20
关键词
Alirocumab; antidrug antibody; bococizumab; cardiovascular diseases; evolocumab; familial hypercholesterolemia; neurocognitive; proprotein convertase subtilisin-kexin type 9 inhibitors
PCSK9 monoclonal antibodies are novel lipid-lowering therapy that have been extensively studied in patients with hypercholesterolemia either as monotherapy or as an add-on to other LLTs. PCSK9 monoclonal antibodies have significantly reduced the low-density lipoprotein cholesterol (LDL-C) plasma level resulting in a better LDL-C goal attainment. The commercially available PCSK9 monoclonal antibodies, alirocumab and evolocumab, have demonstrated reductions in major adverse cardiovascular events such as myocardial infarction, stroke, unstable angina, and the need for coronary revascularization but not mortality. PCSK9 monoclonal antibodies have demonstrated a favorable safety profile. The most reported side effects are mild injection site with no causal relationship proven between the inhibition of PCSK9 and neurocognitive or glycemic adverse events. In this overview, the efficacy and safety of PCSK9 monoclonal antibodies in the treatment of primary and familial hypercholesterolemia will be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据